Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment

Jing, Weihong; Jiang, Mingyue; Fu, Xiaoxue; Yang, Jiaxin; Chen, Lu; Feng, Lu; Xu, Ping; Huang, Wenyan; Yu, Chao; Yang, Zhangyou

doi:10.1016/j.ijbiomac.2022.06.167

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the materials obtained demonstrated cytotoxicity towards the tested cell lines. In turn, Jing et al [203] carried out studies on albuminbased nanocomposites incorporated with N5,N6-Bis(2-fluorophenyl) [1,2,5]oxadiazolo [3,4b]pyrazine-5,6-diamine (BAM15), an active substance that may prevent obesity and its potential symptoms. The experiments performed demonstrated the excellent biocompatibility of prepared carriers and their liver targeting capability, possibly due to the presence of albumin within their structure.…”

Section: Albumin-based Drug Carriersmentioning

confidence: 99%

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

Jamroży,

Kudłacik-Kramarczyk,

Drabczyk

et al. 2024

IJMS

View full text Add to dashboard Cite

Studies on bionanocomposite drug carriers are a key area in the field of active substance delivery, introducing innovative approaches to improve drug therapy. Such drug carriers play a crucial role in enhancing the bioavailability of active substances, affecting therapy efficiency and precision. The targeted delivery of drugs to the targeted sites of action and minimization of toxicity to the body is becoming possible through the use of these advanced carriers. Recent research has focused on bionanocomposite structures based on biopolymers, including lipids, polysaccharides, and proteins. This review paper is focused on the description of lipid-containing nanocomposite carriers (including liposomes, lipid emulsions, lipid nanoparticles, solid lipid nanoparticles, and nanostructured lipid carriers), polysaccharide-containing nanocomposite carriers (including alginate and cellulose), and protein-containing nanocomposite carriers (e.g., gelatin and albumin). It was demonstrated in many investigations that such carriers show the ability to load therapeutic substances efficiently and precisely control drug release. They also demonstrated desirable biocompatibility, which is a promising sign for their potential application in drug therapy. The development of bionanocomposite drug carriers indicates a novel approach to improving drug delivery processes, which has the potential to contribute to significant advances in the field of pharmacology, improving therapeutic efficacy while minimizing side effects.

show abstract

Section: Albumin-based Drug Carriersmentioning

confidence: 99%

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

Jamroży,

Kudłacik-Kramarczyk,

Drabczyk

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Meanwhile, in isolated rat liver mitochondria, BAM15 led to a collapse in membrane potential, elevated respiration rate, and triggered Ca2+ efflux ( 20 ). Similarly, in vivo experiments have demonstrated that BAM15@BSA NPs, a functionalized drug-albumin nanocomposite prepared by co-assembling BAM15 with bovine serum albumin, exhibit a remarkable ability to target the liver, leading to potent anti-obesity effects ( 49 ). Importantly, it proved highly effective in mitigating hepatic steatosis and enhancing the overall therapeutic efficacy for the treatment of NAFLD ( 49 ).…”

Section: Therapeutic Potential Of Bam15 On Specific Disease Contextsmentioning

confidence: 99%

BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases

Xiong,

Zhang,

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

Subcellular organelles dysfunction is implicated in various diseases, including metabolic diseases, neurodegenerative diseases, cancer, and cardiovascular diseases. BAM15, a selective mitochondrial uncoupler, has emerged as a promising therapeutic agent due to its ability to enhance mitochondrial respiration and metabolic flexibility. By disrupting the coupling between electron transport and ATP synthesis, BAM15 dissipates the proton gradient, leading to increased mitochondrial respiration and energy expenditure. This review provides a comprehensive overview of BAM15, including its mechanism of action and potential therapeutic applications in diverse disease contexts. BAM15 has shown promise in obesity by increasing energy expenditure and reducing fat accumulation. In diabetes, it improves glycemic control and reverses insulin resistance. Additionally, BAM15 has potential in non-alcoholic fatty liver disease, sepsis, and cardiovascular diseases by mitigating oxidative stress, modulating inflammatory responses, and promoting cardioprotection. The safety profile of BAM15 is encouraging, with minimal adverse effects and remarkable tolerability. However, challenges such as its high lipophilicity and the need for alternative delivery methods need to be addressed. Further research is necessary to fully understand the therapeutic potential of BAM15 and optimize its application in clinical settings.

show abstract

The function of albumin and its application in tumor therapy

Xu,

Na,

Liu

et al. 2024

Materials Today Communications

View full text Add to dashboard Cite

Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment

Cited by 3 publications

References 30 publications

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases

The function of albumin and its application in tumor therapy

Contact Info

Product

Resources

About